Organisation paid for research Program year 2025 Source: CMS Open Payments

Diagnamics Inc

Neither a doctor nor a teaching hospital

Research payments

$1,475,861

584 payments

Through program year 2025, Diagnamics Inc is reported as receiving $1,475,861 in research payments, across 584 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$557,841	152
2024	Research	$392,768	160
2023	Research	$158,722	83
2022	Research	$61,743	43
2021	Research	$58,532	34
2020	Research	$82,772	55
2019	Research	$163,483	57

Breakdown

Who paid Research payments · program years 2019–2025

AbbVie, Inc. $681,941 186 payments
Sumitomo Pharma America, Inc. $209,911 183 payments
Allergan Inc. $138,891 83 payments
Ortho-Clinical Diagnostics, Inc. $105,890 8 payments
Ironwood Pharmaceuticals, Inc $96,798 26 payments
Visby Medical, Inc. $71,213 9 payments
Genentech, Inc. $70,620 39 payments
Bayer HealthCare Pharmaceuticals Inc. $49,398 34 payments
GlaxoSmithKline, LLC. $42,700 15 payments
Merck Sharp & Dohme Corporation $8,500 1 payment

Studies the money was for Research payments · program years 2019–2025

A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants $440,453 68 payments
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids Or Endometriosis $80,535 66 payments
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants $73,785 18 payments
Clinical Evaluation of the Visby Medical Flu and COVID-19 Test for the Detection and Differentiation of SARS-CoV-2, Influenza A, and Influenza B Viral RNA $71,213 9 payments
Roche Cancer Screening Collection Study $70,620 39 payments
Respiratory Virus Sample Collection $57,390 4 payments
McP-103-312 $57,280 13 payments
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis $52,666 20 payments
A Phase 3 Singlearm Openlabel Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids Or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy $47,922 49 payments
Serene $44,901 24 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.